BioCentury
ARTICLE | Company News

Digna Biotech, Isdin deal

November 21, 2011 8:00 AM UTC

Digna regained exclusive rights from Isdin to P144 to treat skin conditions. The topical formulation of peptide 144 transforming growth factor (TGF) beta 1 (TGFB1) inhibitor completed a Phase IIa trial in systemic sclerosis. Digna said it is seeking a partner for the program. P144 has Orphan Drug designation in the U.S. and EU for systemic sclerosis and localized scleroderma. Details were not disclosed. ...